Ilaprazole PCD Pharma Franchise Company
Cafoli Lifecare offers 3 Ilaprazole formulations across tablets and capsules for PCD pharma franchise and third-party manufacturing. Every batch is produced in WHO-GMP certified facilities, giving distributors a newer proton-pump inhibitor for the large acid-peptic segment.
What is Ilaprazole?
Ilaprazole is a proton-pump inhibitor (PPI). It irreversibly blocks the gastric H+/K+-ATPase enzyme system, strongly and durably suppressing stomach acid secretion. Its long half-life gives sustained acid control compared with some older PPIs. See PubChem for chemical and pharmacological data.
Therapeutic Applications
Ilaprazole is used to treat gastro-oesophageal reflux disease (GERD), peptic and duodenal ulcers, and other acid-related disorders. It is prescribed chiefly by gastroenterologists and general physicians, often in combination with prokinetics such as domperidone.
Why Ilaprazole is a High-Potential Molecule for Distributors
Acidity and GERD form one of India’s largest therapy segments, and while older PPIs are heavily commoditised, ilaprazole is a newer, long-acting alternative with a cleaner competitive field. That lets franchise partners position a premium, differentiated PPI — with domperidone combinations — into a market that already generates dependable, high-repeat demand.
Why Choose Cafoli Lifecare
Cafoli Lifecare supports partners with monopoly PCD rights, WHO-GMP manufacturing, DCGI-approved formulations, complete promotional inputs and a network of 1000+ franchise partners across India.
References
- PubChem – Ilaprazole
- PubMed – Ilaprazole research
- MedlinePlus – Proton-Pump Inhibitors (class information)
Our formulations of Ilaprazole find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: